Immunofixation (Qualitative)

Cancer

Report in 48Hrs

At Home

No Fasting Required

Details

Protein electrophoresis.

₹6,068₹8,669

30% OFF

Immunofixation (Qualitative) - Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Description: Immunofixation is an electrophoretic technique that identifies specific immunoglobulin types and light chains in serum or urine by using specific antisera to precipitate and fix individual protein types. It provides qualitative identification of monoclonal proteins and helps determine their specific immunoglobulin class and light chain type.
- Primary Indications: Detection and characterization of monoclonal gammopathies; diagnosis of multiple myeloma; investigation of suspected light chain disease; monitoring of plasma cell dyscrasias; evaluation of unexplained proteinuria; diagnosis of Waldenström macroglobulinemia; assessment of amyloidosis; follow-up of patients with paraproteinemia
- Typical Timing/Circumstances: Ordered when serum or urine protein electrophoresis demonstrates an abnormal spike or M-spike; during initial workup of suspected hematologic malignancy; in patients with elevated total protein or albumin-to-globulin ratio abnormalities; when screening for monoclonal proteins; during monitoring of known myeloma or related disorders; when evaluating symptoms suggestive of plasma cell dyscrasia
Section 2: Normal Range
- Normal Result Interpretation: NEGATIVE (No monoclonal protein identified); No discrete bands in immunoglobulin regions; Polyclonal immunoglobulin pattern only
- Reference Range Values: This is a qualitative test with categorical results rather than numerical values. Results are reported as: • Negative: No monoclonal protein detected • Positive: Identifies specific immunoglobulin type (IgG, IgA, IgM, IgD, IgE) and light chain type (Kappa or Lambda)
- Units of Measurement: Qualitative (Positive/Negative); Semi-quantitative assessment of band intensity may be noted (Trace, 1+, 2+, 3+, 4+)
- Normal vs Abnormal Interpretation: Normal (Negative): Absence of monoclonal proteins; only polyclonal immunoglobulins present; suggests no plasma cell dyscrasia • Abnormal (Positive): Presence of monoclonal protein with specific immunoglobulin class and light chain; indicates monoclonal gammopathy; requires further clinical correlation and quantification
Section 3: Interpretation
- Detailed Result Interpretation: NEGATIVE Result: No monoclonal protein identified; indicates absence of significant clonal proliferation; may rule out multiple myeloma, Waldenström macroglobulinemia, and light chain disease • POSITIVE IgG Kappa/Lambda: Most common finding (~50-60% of multiple myeloma cases); may indicate IgG myeloma or other IgG monoclonal gammopathy • POSITIVE IgA Kappa/Lambda: Found in ~20-25% of multiple myeloma; associated with IgA myeloma • POSITIVE IgM Kappa/Lambda: Characteristic of Waldenström macroglobulinemia; classic presentation of lymphoplasmacytic lymphoma • POSITIVE Light Chain Only (Bence Jones proteinuria): Indicates light chain myeloma or light chain disease; may be associated with renal failure • POSITIVE IgD or IgE: Rare presentations (<2% of myeloma cases); unusual monoclonal gammopathies
- Clinical Significance of Patterns: Monoclonal Pattern: Single discrete band indicates clonal proliferation; highly specific for plasma cell dyscrasia • Polyclonal Pattern: Multiple bands with varying intensities; normal finding; suggests no significant monoclonal process • Biclonal Pattern: Two distinct monoclonal proteins; may indicate dual myeloma or coexisting gammopathies • Band Intensity: Correlates roughly with protein concentration; higher intensity suggests greater paraprotein burden
- Factors Affecting Results: Specimen quality and preservation; time from collection to analysis; anticoagulant type (serum preferred over plasma); prior chemotherapy or immunosuppressive therapy; recent transfusions; concurrent infections affecting polyclonal immunoglobulins; hemolysis or contamination; patient hydration status affecting protein concentration
- Clinical Significance Summary: Immunofixation provides definitive identification of monoclonal proteins essential for diagnosis and classification of plasma cell dyscrasias; enables targeted therapy selection based on protein type; critical for distinguishing myeloma from benign monoclonal gammopathy of undetermined significance (MGUS); helps identify nonsecretory myeloma when combined with other findings; useful for monitoring treatment response and detecting relapse
Section 4: Associated Organs
- Primary Organ Systems Involved: Bone marrow (primary site of malignant plasma cell proliferation); blood/hematologic system (circulation of monoclonal proteins); kidneys (filtration and reabsorption of light chains; potential target organ damage)
- Diseases Associated with Abnormal Results: Multiple Myeloma: Most common plasma cell malignancy; characterized by clonal bone marrow infiltration • Waldenström Macroglobulinemia: Malignant lymphoplasmacytic lymphoma producing IgM paraprotein • Light Chain Myeloma: Myeloma producing only free light chains; high renal toxicity • Benign Monoclonal Gammopathy of Undetermined Significance (MGUS): Nonprogressive monoclonal protein <3 g/dL • AL Amyloidosis: Misfolded monoclonal protein forming amyloid deposits in organs • Monoclonal Gammopathy of Renal Significance (MGRS): Monoclonal protein causing kidney dysfunction • Primary Macroglobulinemia: IgM-secreting lymphoproliferative disorder • IgD and IgE Myeloma: Rare myeloma subtypes with aggressive behavior
- Potential Complications of Abnormal Results: Renal failure from light chain nephropathy ("myeloma kidney"); bone disease with pathologic fractures and hypercalcemia; anemia from bone marrow infiltration; hyperviscosity syndrome from high IgM levels; amyloid organ infiltration; bacterial infections from immunosuppression; spinal cord compression; neurological complications from light chains; cardiac dysfunction from amyloidosis
- Target Organ Damage: Kidneys: Primary target for light chain toxicity causing acute tubular necrosis and chronic kidney disease • Bones: Lytic lesions, osteoporosis, pathologic fractures • Nervous System: Peripheral neuropathy, spinal involvement, amyloid deposition • Heart: Restrictive cardiomyopathy from amyloidosis • Liver: Amyloid infiltration • Gastrointestinal tract: Bleeding, perforation from amyloid vasculitis
Section 5: Follow-up Tests
- Recommended Follow-up Tests if Positive: Serum Quantitative Immunoglobulins: Quantifies absolute levels of IgG, IgA, IgM, IgD, IgE • Free Light Chains Assay: Measures serum free kappa and lambda light chains; assesses FLC ratio • 24-Hour Urine Protein Electrophoresis: Quantifies light chain excretion in urine • Beta-2 Microglobulin: Prognostic marker for myeloma • Bone Marrow Biopsy: Assesses percentage of clonal plasma cells; evaluates for myeloma criteria • Complete Blood Count (CBC): Evaluates for anemia, leukopenia, thrombocytopenia • Comprehensive Metabolic Panel: Assesses renal function, calcium levels, creatinine • Serum Creatinine and Blood Urea Nitrogen (BUN): Evaluates renal involvement
- Further Investigations for Diagnosis: Skeletal Survey or Whole-Body PET-CT: Assesses for lytic bone lesions • MRI Spine: Evaluates for bone marrow involvement and cord compression • Flow Cytometry: Characterizes bone marrow plasma cell population • Cytogenetics/FISH: Identifies high-risk genetic abnormalities (t(4;14), t(14;16), del(17p)) • Serum Viscosity: Measured if hyperviscosity syndrome suspected • Urine Dipstick and Microscopy: Detects proteinuria and cellular casts • Tissue Biopsy: Assessed for amyloid if AL amyloidosis suspected • Echocardiogram: Evaluates for cardiac amyloidosis if indicated
- Monitoring Frequency for Known Conditions: Active Multiple Myeloma: Serum and urine immunofixation every 1-3 months during treatment; monthly during intensive therapy • MGUS: Immunofixation annually to assess stability; more frequently if progressing • Post-Transplant: Immunofixation at 1, 3, 6, and 12 months then annually • Remission Maintenance: Every 3-6 months or per institutional protocol • Relapsed/Refractory Disease: As clinically indicated, typically monthly to quarterly
- Complementary Tests for Comprehensive Assessment: Serum Protein Electrophoresis (SPEP): Provides visual pattern and estimates paraprotein concentration • Urine Protein Electrophoresis (UPEP): Characterizes urinary light chains • Albumin Level: Assesses nutritional status and establishes baseline • Lactate Dehydrogenase (LDH): Prognostic marker; elevated in aggressive disease • Calcium Level: Assesses for hypercalcemia complications • C-Reactive Protein (CRP): Inflammatory marker and prognostic indicator • Hemoglobin and Hematocrit: Monitors for myeloma-related anemia
Section 6: Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for immunofixation testing
- Patient Preparation Instructions: No fasting period required; patient may eat and drink normally before testing • No fluid restriction needed; normal hydration is acceptable • Patient may take all regular medications unless specifically instructed otherwise • Blood should be drawn via venipuncture into a serum separator tube (SST) for serum specimens • For urine immunofixation: first morning void or 24-hour urine collection per lab protocol
- Medications to Avoid: No specific medications need to be withheld for immunofixation testing • Continue all regular medications as prescribed • Inform laboratory and physician of all current medications for result interpretation context
- Special Preparation Requirements: Serum Specimen: Allow blood to clot at room temperature for 30 minutes; separate serum within 2 hours of collection; refrigerate or freeze if analysis cannot be performed immediately • Urine Specimen: Obtain clean-catch midstream sample for spot collection or 24-hour urine in appropriate container; refrigerate until transport to laboratory; do not freeze unless specifically instructed • Specimen Stability: Room temperature 3 hours; refrigerated 7 days; frozen (-20°C) 30 days • Timing: Preferably collect specimens before chemotherapy or immunosuppressive therapy initiation when evaluating for baseline paraprotein
- Additional Information: Immunofixation can be performed on serum, urine, or cerebrospinal fluid (CSF) specimens depending on clinical indication • Specimen quality critical: hemolyzed, lipemic, or contaminated samples may be rejected • Results typically available within 1-3 business days • Consultation with laboratory advisable for unusual presentations or specimen concerns • Repeat testing may be necessary if initial specimen is inadequate

How our test process works!